Evidence map›Paper›PMID 40272708›Full record

ArticleDrug delivery and translational research2026

Oral peptide drug delivery: design of SEDDS providing a protective effect against intestinal membrane-bound enzymes.

Annika Postina, Dennis To, Katrin Zöller, Andreas Bernkop-Schnürch

Abstract read
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Annika PostinaCenter for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.
Dennis ToCenter for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.
Katrin ZöllerCenter for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria.
Andreas Bernkop-SchnürchCenter for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University of Innsbruck, Innrain 80/82, 6020, Innsbruck, Austria. Andreas.Bernkop@uibk.ac.at.ORCID http://orcid.org/0000-0003-4187-8277

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presents an emerging approach for oral peptide drug delivery by designing self-emulsifying drug delivery systems (SEDDS) capable of protecting peptide drugs from intestinal brush border membrane-bound (BBM) enzymes. Tuftsin was incorporated as a model peptide into three optimized SEDDS formulations through hydrophobic ion pairing with the anionic surfactants docusate (AOT), N-octadecyl sulfate (OS), and lauryl sulfate (LS). SEDDS- 1 consisted of octyldodecanol, polyoxyethylene (10) oleyl ether, polyoxyethylene (20) oleyl ether and citronellol. SEDDS- 2 were formulated with isopropylmyristate, polyoxyethylene (20) oleyl ether and eugenol. SEDDS- 3 included caprylic acid, PEG- 35 castor oil and citronellol. The resulting nanoemulsions were characterized for droplet size, zeta potential, polydispersity index (PDI), and stability in biorelevant media. Enzymatic degradation studies with aminopeptidase N and ex vivo rat small intestine revealed remarkable protective effects. SEDDS- 3 exhibited superior performance, preserving over 80% of tuftsin after 4 h, followed by SEDDS- 2 protecting 70% of tuftsin, while the unformulated peptide was entirely degraded within 20 min. Furthermore, SEDDS- 2 demonstrated enhanced permeation of tuftsin across intestinal mucosa by achieving a 4-fold increase, while SEDDS- 3 led to a 3-fold enhancement in permeation compared to the unformulated peptide. Accordingly, SEDDS- 3 demonstrates the greatest potential for peptide delivery due to its superior protective performance and enhanced permeation compared to the control. These findings underscore the potential of SEDDS as a versatile platform for safeguarding peptide drugs against enzymatic degradation in the intestinal environment. By modifying their composition, SEDDS can unlock new possibilities for efficient oral peptide drug delivery, overcoming critical enzymatic and mucosal barriers.

Indexed as

Drug Delivery SystemsPeptidesAdministration, OralAnimalsEmulsionsIntestinal MucosaMaleRatsRats, Sprague-DawleySurface-Active AgentsEmulsionsPeptidesSurface-Active AgentsHydrophobic ion pairingMembrane-bound enzymeOral drug deliveryPeptide drugsSEDDS

Identifiers

PMID40272708
PMCPMC13294191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.